Inovio Pharmaceuticals Inc. [NASDAQ: INO] traded at a high on 04/06/23, posting a 10.29 gain after which it closed the day’ session at $0.77. The company report on April 3, 2023 that INOVIO Reports Inducement Grant Under Inducement Plan.
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the “Inducement Plan”).
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The Compensation Committee of INOVIO’s Board of Directors has approved the award of restricted stock units (“RSUs”) covering an aggregate of 45,000 shares of common stock and options to purchase an aggregate of 70,000 shares of common stock, with a grant date of March 31, 2023 (the “Grant Date”), to the newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The results of the trading session contributed to over 10611879 shares changing hands. Over the past one week, the price volatility of Inovio Pharmaceuticals Inc. stands at 9.41% while the volatility over the past one month is 7.80%.
The market cap for INO stock reached $183.18 million, with 250.59 million shares outstanding and 245.68 million shares in the current float. Compared to the average trading volume of 4.80M shares, INO reached a trading volume of 10611879 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Inovio Pharmaceuticals Inc. [INO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $1.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 09, 2022. The new note on the price target was released on November 01, 2022, representing the official price target for Inovio Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $5 to $4, while RBC Capital Mkts kept a Sector Perform rating on INO stock.
The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 0.08, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 17.78. The Price to Book ratio for the last quarter was 0.86, with the Price to Cash per share for the same quarter was set at 1.06.
How has INO stock performed recently?
Inovio Pharmaceuticals Inc. [INO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.87. With this latest performance, INO shares dropped by -35.34% in over the last four-week period, additionally sinking by -57.01% over the last 6 months – not to mention a drop of -79.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 29.08, with the RSI for the last a single of trading hit 31.00, and the three-weeks RSI is set at 30.07 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 1.2757, while it was recorded at 0.7584 for the last single week of trading, and 1.7984 for the last 200 days.
Inovio Pharmaceuticals Inc. [INO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -2672.64 and a Gross Margin at +46.44. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -2726.67.
Return on Total Capital for INO is now -79.83, given the latest momentum, and Return on Invested Capital for the company is -82.09. Return on Equity for this stock declined to -89.97, with Return on Assets sitting at -65.86. When it comes to the capital structure of this company, Inovio Pharmaceuticals Inc. [INO] has a Total Debt to Total Equity ratio set at 14.42. Additionally, INO Total Debt to Total Capital is recorded at 12.61, with Total Debt to Total Assets ending up at 9.14. Long-Term Debt to Equity for the company is recorded at 13.16, with the Long-Term Debt to Total Capital now at 11.50.
Reflecting on the efficiency of the workforce at the company, Inovio Pharmaceuticals Inc. [INO] managed to generate an average of -$1,520,750 per employee. Receivables Turnover for the company is 1.04 with a Total Asset Turnover recorded at a value of 0.02.Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.
Earnings analysis for Inovio Pharmaceuticals Inc. [INO]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc. go to 41.50%.
Insider trade positions for Inovio Pharmaceuticals Inc. [INO]
There are presently around $98 million, or 47.80% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: STATE STREET CORP with ownership of 31,472,352, which is approximately 20.927% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 23,284,119 shares of the stock with an approximate value of $17.91 million in INO stocks shares; and VANGUARD GROUP INC, currently with $13.11 million in INO stock with ownership of nearly 10.793% of the company’s market capitalization.
Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 91 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 18,833,909 shares. Additionally, 72 investors decreased positions by around 8,869,609 shares, while 48 investors held positions by with 99,631,800 shares. The mentioned changes placed institutional holdings at 127,335,318 shares, according to the latest SEC report filing. INO stock had 31 new institutional investments in for a total of 638,856 shares, while 25 institutional investors sold positions of 1,936,206 shares during the same period.